Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted DA-EPOCH-R for newly diagnosed Burkitt lymphoma
NL-OMON36941Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and 1 more in Burkitt lymphoma (BL), sponsored by Vrije University Medical Center. Primary endpoints: 2-year overall survival, 2-year progression-free survival and 1 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
rituximabetoposideprednisonevincristinecyclophosphamide
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NL-OMON36941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36941.